Gamida Cell Ltd (NASDAQ:GMDA) Expected to Announce Earnings of -$0.29 Per Share

Equities analysts expect Gamida Cell Ltd (NASDAQ:GMDA) to report earnings per share (EPS) of ($0.29) for the current quarter, according to Zacks. Zero analysts have provided estimates for Gamida Cell’s earnings, with estimates ranging from ($0.32) to ($0.26). Gamida Cell posted earnings of ($0.30) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 3.3%. The business is expected to report its next earnings report on Wednesday, November 11th.

According to Zacks, analysts expect that Gamida Cell will report full-year earnings of ($1.29) per share for the current financial year, with EPS estimates ranging from ($1.40) to ($1.19). For the next fiscal year, analysts expect that the business will report earnings of ($1.14) per share, with EPS estimates ranging from ($1.32) to ($0.89). Zacks’ EPS calculations are an average based on a survey of research firms that follow Gamida Cell.

Gamida Cell (NASDAQ:GMDA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.11).

Several brokerages have issued reports on GMDA. HC Wainwright restated a “buy” rating on shares of Gamida Cell in a research note on Thursday, August 13th. Needham & Company LLC reiterated a “buy” rating and set a $17.00 price objective on shares of Gamida Cell in a research note on Thursday. Oppenheimer reiterated a “buy” rating and set a $20.00 price objective on shares of Gamida Cell in a research note on Thursday. Evercore ISI initiated coverage on Gamida Cell in a research report on Tuesday, June 30th. They set an “outperform” rating for the company. Finally, Zacks Investment Research cut Gamida Cell from a “hold” rating to a “sell” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Gamida Cell has a consensus rating of “Buy” and an average target price of $14.83.

Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of Gamida Cell by 73.4% in the 2nd quarter. FMR LLC now owns 4,900,426 shares of the company’s stock worth $22,395,000 after purchasing an additional 2,073,885 shares in the last quarter. BVF Inc. IL boosted its holdings in shares of Gamida Cell by 114.4% in the 2nd quarter. BVF Inc. IL now owns 2,143,667 shares of the company’s stock worth $9,797,000 after purchasing an additional 1,143,667 shares in the last quarter. Driehaus Capital Management LLC purchased a new position in shares of Gamida Cell in the 2nd quarter worth about $8,732,000. Federated Hermes Inc. purchased a new position in shares of Gamida Cell in the 2nd quarter worth about $8,124,000. Finally, Alyeska Investment Group L.P. boosted its holdings in shares of Gamida Cell by 412.8% in the 2nd quarter. Alyeska Investment Group L.P. now owns 1,097,151 shares of the company’s stock worth $5,014,000 after purchasing an additional 883,198 shares in the last quarter. Hedge funds and other institutional investors own 66.24% of the company’s stock.

Shares of GMDA traded up $0.14 during mid-day trading on Friday, hitting $4.25. The stock had a trading volume of 76,986 shares, compared to its average volume of 188,511. The firm has a market cap of $102.94 million, a P/E ratio of -2.97 and a beta of 1.93. The business has a fifty day moving average price of $4.22 and a 200-day moving average price of $4.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 6.69 and a quick ratio of 6.69. Gamida Cell has a 52 week low of $2.60 and a 52 week high of $7.70.

About Gamida Cell

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia.

Further Reading: How does a reverse stock split work?

Get a free copy of the Zacks research report on Gamida Cell (GMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.